Caremo Shortlisted for 2023 Venture50 "Budding List "

Recently, the 2023 Venture50 Preliminary Results, organized by Zero2IPO Group (1945.HK), were announced. Among over 4,000 participating enterprises, Caremo stood out and secured a spot in the 2023 Venture50 Budding List Ranking.

Launched in 2006 by Zero2IPO Group (1945.HK), the Venture50 (V50) has become a benchmark for identifying high-growth, high-value enterprises in China over its 18-year evolution. The ranking categorizes companies into two lists—"Fengyun Ranking" (established enterprises) and "Budding Ranking" (emerging startups)—creating a multidimensional platform for startups and investors. As of October 2023, the initiative has evaluated 75,000+ enterprises, facilitated over RMB 239.456 billion in financing for listed companies, with a 49.25% follow-on financing rate and ~15.27% IPO rate.

For the 2023 ranking, hundreds of judges from top-tier investment institutions assessed candidates based on innovation, forward-looking vision, growth potential, feasibility, and uniqueness. After five months of rigorous screening and due diligence, Caremo emerged as one of the Top 200 Budding List, recognized for its technical prowess, core competitive advantages, and rapid growth trajectory.

This accolade affirms Caremo’s R&D capabilities, strategic market performance, and industrialization potential. Since its establishment in June 2020, Caremo has adhered to its mission—“Born for Health, Empowered for Innovation”—by integrating core technologies across innovative and generic drug development through a dual-drive strategy of R&D and industrialization. The company delivers customized solutions tailored to diverse client needs.

To date，Caremo’s milestones include certifications and honors such as:

- National High-Tech Enterprise

- Technology-based SME

- Jiangsu Provincial Private Technology Enterprise

- 2023 Jiangsu Potential Unicorn Enterprise

- Nanjing Municipal Special Dosage Form Drug Engineering Technology Research Center

- “2023 Most Competitive Pharmaceutical Service Enterprise in China”

- “2022-2023 Top 50 Chinese Pharmaceutical R&D Enterprises”

- “2023 Top 20 Chinese R&D CRO Enterprises”

The 2023 Budding List Top 50 Ranking will be officially unveiled in early 2024. Let’s stay tuned!